Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
28 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Ocugen, Inc.’s names, not what it holds today.
Patents granted
28
28 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against none in 2024 and 2 in 2023
Applications published
44
2 of them in 2025
Names they are printed under
3
a former name, its own name
By yearGrantedApplications published
'09'11'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Medical technology3
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
Histogenics Corporation a former name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in GB)
22 publishedOcugen, Inc. its own name
US, as the owner printed on each patent
12 publishedHistogenics Corporation a former name
named as the applicant on its applications, in US
10 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jul 1, 2025 | 12,344,860 | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof | Medical technology | Ocugen, Inc. |
| May 16, 2023 | 11,648,102 | Method for use of a double-structured tissue implant for treatment of tissue | Medical technology | Ocugen, Inc. |
| Jan 17, 2023 | 11,555,172 | Cell and tissue culture container | Biotechnology | Ocugen, Inc. |
| Jan 26, 2021 | 10,900,017 | Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof | Medical technology | Histogenics Corporation |
| Nov 24, 2020 | 10,842,610 | Method for use of a double-structured tissue implant for treatment of tissue defects | Medical technology | Histogenics Corporation |
| Aug 25, 2020 | 10,751,337 | Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders | Pharmaceuticals | Ocugen, Inc. |
| Feb 11, 2020 | 10,555,947 | Ophthalmic compositions and methods of use | Pharmaceuticals | Ocugen, Inc. |
| Sep 18, 2018 | 10,077,420 | Cell and tissue culture container | Biotechnology | Histogenics Corporation |
| Jun 12, 2018 | 9,993,326 | Method for use of a double-structured tissue implant for treatment of tissue defects | Medical technology | Histogenics Corporation |
| Jan 30, 2018 | 9,877,964 | Methods and compositions for treating dry eye disease and other eye disorders | Pharmaceuticals | Ocugen, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| May 29, 2025 | 2025/0171736 | Cell-Support Matrix Having Narrowly Defined Uniformly Vertically and Non-Randomly Organized Porosity and Pore Density and a Method For Preparation Thereof | Medical technology | Ocugen, Inc. |
| Feb 13, 2025 | 2025/0049912 | Multicistronic Vaccine and Methods for Producing and Using the Same | Pharmaceuticals | Ocugen, Inc. |
| May 9, 2024 | 2024/0148830 | Treatment of Neurological Disorder Using NHR | Pharmaceuticals | Ocugen, Inc. |
| Sep 7, 2023 | 2023/0277291 | METHOD FOR USE OF A DOUBLE-STRUCTURED TISSUE IMPLANT FOR TREATMENT OF TISSUE DEFECTS | Medical technology | Ocugen, Inc. |
| Aug 25, 2022 | 2022/0265900 | NEOCARTILAGE CONSTRUCTS USING UNIVERSAL CELLS | Medical technology | Histogenics Corporation |
| Aug 12, 2021 | 2021/0246418 | CELL-SUPPORT MATRIX HAVING NARROWLY DEFINED UNIFORMLY VERTICALLY AND NON-RANDOMLY ORGANIZED POROSITY AND PORE DENSITY AND A METHOD FOR PREPARATION THEREOF | Medical technology | Histogenics Corporation · patent 12,344,860 granted from it |
| Jun 3, 2021 | 2021/0161672 | SCAFFOLD WITH ADHESIVE FOR ARTICULAR CARTILAGE REPAIR | Medical technology | Histogenics Corporation |
| Apr 29, 2021 | 2021/0123077 | ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASES | Pharmaceuticals | Ocugen, Inc. |
| Mar 4, 2021 | 2021/0059805 | METHOD FOR USE OF A DOUBLE-STRUCTURED TISSUE IMPLANT FOR TREATMENT OF TISSUE DEFECTS | Medical technology | Histogenics Corporation · patent 11,648,102 granted from it |
| Jul 16, 2020 | 2020/0224155 | CELL-SUPPORT MATRIX HAVING NARROWLY DEFINED UNIFORMLY VERTICALLY AND NON-RANDOMLY ORGANIZED POROSITY AND PORE DENSITY AND A METHOD FOR PREPARATION THEREOF | Medical technology | Histogenics Corporation · patent 10,900,017 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 2 · Medical technology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.